Bio-Path Holdings announced positive preclinical results for BP1001-A, a potential obesity and Type 2 diabetes treatment. The drug candidate successfully reversed palmitic acid-induced insulin resistance in liver cells, mirroring earlier positive results in muscle cells. This progress builds on previous findings demonstrating the drug’s ability to restore insulin signaling by downregulating Grb2 expression.
This development is potentially impactful for addressing the growing prevalence of obesity and Type 2 diabetes, conditions often linked to insulin resistance. A successful therapy targeting this mechanism could offer a new approach to managing these interconnected metabolic disorders, improving patient outcomes and potentially reducing the burden on healthcare systems. Specifically, the ability of BP1001-A to counteract the negative effects of a high-fat diet at the cellular level suggests it may be effective in preventing or treating insulin resistance, a key driver of these diseases.
BP1001-A, a modified version of Bio-Path’s prexigebersen (BP1001) currently in Phase 2 trials for blood cancers, functions by downregulating Grb2, a protein involved in insulin signaling. The next preclinical step involves testing in a mouse model to assess the drug’s impact on weight, insulin sensitivity, and glucose tolerance. Pending positive results, Bio-Path anticipates filing an Investigational New Drug (IND) application in 2025 for a Phase 1 clinical trial.
These preclinical findings are a promising step toward a potential new therapeutic option for obesity and Type 2 diabetes. Success in the upcoming animal studies and subsequent clinical trials could position BP1001-A as a valuable asset in Bio-Path’s pipeline, potentially expanding the drug’s application beyond oncology into metabolic disease. Further research will be crucial to determining its efficacy and safety in humans.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
12 Comments
MetaVia’s DA-1726 Reaches Highest Doses in Phase 1 Study Ahead of 2026 Results
2 months ago[…] combination backbone, presenting preclinical synergy data with resmetirom in MASH and metformin in type 2 diabetes at ADA 2026. An End-of-Phase 2 meeting with the FDA is being scheduled for the second half of 2026 […]
The GLP-1 Mood Signal Is Real — But So Is the Psychiatric Worsening Risk
1 month ago[…] close to 100,000 Swedish patients with depression or anxiety who also carried a diagnosis of type 2 diabetes or obesity. Those treated with semaglutide showed lower rates of psychiatric deterioration compared […]
NewAmsterdam Pharma Wins CHMP Opinion for Obicetrapib Cholesterol Drug
3 weeks ago[…] an Alzheimer’s prevention trial later this year. The RUBENS Phase 3, targeting patients with type 2 diabetes or metabolic syndrome, is expected to report topline data before year-end, adding a third […]
LITMUS Changes the Biopsy Calculus: What the Nature Medicine Data Means for Your MASLD Protocol
3 weeks ago[…] of the world’s adult population meets diagnostic criteria, and prevalence among people with type 2 diabetes exceeds 70% in the U.S. The commercial opportunity is driving trial volume fast. Resmetirom […]
Survodutide Phase III trial shows 34% visceral fat, 63% liver fat reduction
3 weeks ago[…] that argument across two distinct populations. In SYNCHRONIZE-1, adults with obesity but without type 2 diabetes lost up to 34% of visceral fat and up to 63.1% of liver fat relative to baseline — reductions […]
Retatrutide Shows 28.3% Weight Loss in Phase 3 Obesity Trial
3 weeks ago[…] TRANSCEND-T2D-1 trial adds a second pressure point: 16.8% body weight reduction in patients with type 2 diabetes, a population that consistently underperforms on weight-loss endpoints with existing agents. That […]
Aleniglipron’s Phase 2b Data Redraws the Oral GLP-1 Efficacy Map — And Raises Hard Questions for Phase 3 Design
3 weeks ago[…] Nordisk’s oral semaglutide (Rybelsus) received FDA approval in September 2019 — but for type 2 diabetes, not obesity, and at doses of 7 mg and 14 mg that were not optimized for weight reduction. The […]
Semaglutide’s Alcohol Data Is Stronger Than Anyone Expected — and the FDA Has No Playbook for It
3 weeks ago[…] at a clinical threshold. And semaglutide, a drug approved for chronic weight management and type 2 diabetes, delivered robust therapeutic effects across both conditions simultaneously. That is not an […]
Apotex Gets Health Canada Approval for Generic Semaglutide
3 weeks ago[…] involved. No Canadian generics company had cleared this bar before. The indication is confined to type 2 diabetes and glycemic control in adults alongside diet and exercise, which mirrors Ozempic’s approved […]
Semaglutide Just Passed Its Hardest Test Yet — And the FDA Has No Roadmap for What Comes Next
3 weeks ago[…] 2.4 mg produced a mean body weight reduction of 14.9% from baseline over 68 weeks in adults without type 2 diabetes. Cardiovascular risk reduction followed: on March 8, 2024, the FDA approved Wegovy for a new […]
The Imaging Gap in GLP-1 Trials: Why the Most Important Data May Not Be in Your Protocol
3 weeks ago[…] The metabolic phenotype is the one associated with obesity, insulin resistance, hypertension, and type 2 diabetes — what we know as metabolic syndrome. That is in theory the subgroup most likely to respond to a […]
The GLP-1 Pill Just Broke Every Obesity Trial Playbook
3 weeks ago[…] actual GLP-1 oral adherence data. Semaglutide’s oral formulation — approved by the FDA for type 2 diabetes in 2019 under the brand name Rybelsus — requires administration with no more than 4 ounces of […]
Comments are closed.